Vox Valor Capital Share Discussion Threads

[gwr7] 02/8/2007 18:36

I've created a new thread for Summit Corporation (SUMM).
This one is now deceased. There will be a quiet ceremony, family and close friends only please.

[grim] 25/7/2007 22:02

recent con to Summitt has caused a new ticker of SUMM to be issued.

[gwr7] 16/5/2007 18:31

Momentum building within the company is not reflected in the share price. Let it sleep while you build your stake. It will rise when it's ready.

[gwr7] 09/5/2007 19:55

Keep it to yourself or there'll be a stampede.

[maiseymouse] 01/5/2007 07:09

an interesting little nugget?

[maiseymouse] 01/5/2007 07:09

an interesting little nugget?

[gwr7] 29/3/2007 09:13

CE purchases shares, results announcement pushed back one week to 29th May to accomodate and closed period now starts today. Three directors obtained shares yesterday probably in lieu of salary as announced earlier.

[gwr7] 23/3/2007 10:04

Director share purchase reported on 22nd March, last day before 2 month closed period prior to results on 22nd May. Could be significant.

[dr biotech] 06/3/2007 11:21

This one is a bit too early stage for me. Its well funded and has some interesting ideas, but they are probably a couple of years away even from PI trials.

I'm not sure either whether it is a drug discovery group or a speciality services group or both (I think they are better focusing in one area). Perhaps one for the future.

[gwr7] 13/2/2007 18:08

Hello, is there anybody out there?

[siri_edit] 21/10/2004 11:47

post removed by ADVFN

[cezary] 20/10/2004 09:48

http://www.vastox.com/i/navi/logo.gif">


VASTox plc, the Oxford-based drug discovery and services business focused on chemical genomics, announces its intention to join the Alternative Investment Market (AIM) by way of a Placing.

The Company has early-stage proprietary research programmes in Duchenne Muscular Dystrophy and Tuberculosis and also has revenue-generating contracts for the provision of drug discovery services with several pharmaceutical and biotechnology companies via its chemical genomics platform.

VASTox was formed as a spin-out company in January 2003 by a prestigious team of scientific founders from the University of Oxford headed by Professor Steve Davies, the chemistry professor who in 1992 founded Oxford Asymmetry, a business that was eventually sold for £316 million.

Professor Steve Davies is VASTox's Non-executive Chairman and its Chief Executive Officer is Dr Steven Lee, the former executive director of Life Sciences at IP2IPO Group plc

During the past four years, VASTox's scientific founders whose experience brings together chemistry and biology in an effort to find new treatments for human disease, have collaborated extensively in the development of chemical genomics, the use of small molecule drugs to influence complex cellular pathways. Through its founders, the Company has extensive expertise in the use and understanding of small animal models, in particular Danio rerio (zebrafish) and Drosophila (fruitflies), and applying this to human disease.